Medigen Vaccine Biologics Corporation announced that MVC COVID-19 Vaccine is a vaccine candidates included in WHO's Solidarity Trial Vaccines (STV), a multi center, multi vaccine, adaptive, shared placebo, event driven, individually randomized controlled Phase 3 clinical trial. Recruitment for STV for the purposes of MVC COVID-19 Vaccine has been completed across three countries, Colombia, Mali and the Philippines. To date, approximately 18,000 participants have been enrolled for the evaluation of MVC COVID-19 Vaccine.

Nearly all participants have completed their two dose regimen of either placebo or vaccine. Once participants have completed their two dose regimen, the data will be analyzed by two independent statisticians. Once the statisticians have provided their analysis, this clinical data will be further evaluated by a panel of experts in the STV steering committee.

Upon completion of analysis of the interim data, the results will be published for the review by the scientific community and public at large.